As the year 2023 ended, it is indeed a quantum of solace in terms of finding all TB worldwide. Globally we could find a record number of new TB cases in a single year – historically. Over 7.5 million new TB cases were diagnosed in 2022 worldwide – highest ever in the age-old fight against TB (as per the latest Global TB Report of the UN health agency, the World Health Organisation (WHO) which was released in November 2023).
Finding more TB cases is an important benchmark but not able to find all TB cases continues to be worrisome. Out of the 10.6 million estimated people with TB, we at best have reached out to 7.5 million people so far in 2022.
To end TB, we need to find all TB cases, diagnose all of them by using WHO approved molecular tests upfront and link them to the full cascade of effective treatment, care, and support services. Early and accurate TB diagnosis is an important and critical entry-gate to the TB care pathway. It not only helps in reducing TB-related human suffering but also helps in stopping the spread of infection.
That is why WHO’s highest level initiative – Find.Treat.All (first launched in 2018) – had called upon all governments to replace the old and poorly performing microscopy TB test with WHO recommended rapid molecular tests by 2027. World leaders at the 2023 UN High Level Meeting on TB had also re-echoed this call to completely phase out microscopy with upfront molecular test diagnosis for TB by 2027.
While we cheer those who have worked hard to find the most TB in a single year historically, we also need to realise that we could have done much better. Of the 7.5 million new people who were diagnosed with TB in 2022, only 47 per cent were diagnosed using a WHO recommended molecular test. In other words, more than half of them got the underperforming and outdated microscopy test. This is so unacceptable as we cannot afford to miss TB. India, which carries the highest TB burden globally, set three important records in 2022 as per the government’s India TB Reports of 2022 and 2023.
Record-1: First, the good record. India saw the largest-ever rollout of WHO recommended molecular tests across the nation. Lessons learnt in India’s rollout of molecular testing upfront for finding TB will be an important guiding light for so many more high TB burden nations.
Two Indian states (Goa and Lakshadweep) have completely phased out microscopy and transitioned to 100 per cent use of molecular tests while one Indian state (Andhra Pradesh) is majorly using molecular tests (~70 per cent) and has reduced microscopy. Most of the other Indian states have also increased the use of molecular tests manifold and are at different levels of scaling it up (but are they phasing out microscopy?).
Record-2: Second, the not-so-good record. While the use of molecular testing has seen a rapid rise, the country also increased (not decreased) the use of microscopy for finding TB to a record level in 2022. Over 13.9 million microscopy tests were done in 2022 in India (a record so far) as compared to 8.9 million such tests done in 2021 for finding TB. Earlier in 2018, India had recorded its previous high use of microscopy at 12.1 million.
Numbers do not always tell the full story. As per the WHO Global TB Reports, the use of upfront molecular tests in diagnosing TB rose globally from 38 per cent in 2021 to 47 per cent in 2022 – an increase of 9 per cent. In India, the use of molecular tests grew from 22.4 per cent in 2021 to 23 per cent in 2022 – an increase of 0.6 per cent – but the number 0.6 per cent does not tell the real story. Let’s dive a bit deeper.
Molecular testing grew by 82 per cent in India in 2022 as compared to the levels in 2021 – this is the largest jump in molecular testing figures so far. But this feat is not reflected in the figure of “0.6 per cent” (22.4 per cent to 23 per cent increase during 2021-2022) when we compare the number of molecular tests done with the overall use of TB testing in the country in 2021 and 2022. This is because the creditable increase in molecular testing was offset by the meteoric rise in microscopy also. Microscopy should have reduced and not increased (both – in terms of proportion and numbers)! Thus, during 2021-22 the use of molecular tests in India grew at a record pace, but the growth in microscopy was the steepest in 2022.
As compared to 2021, in 2022 India increased the rollout of WHO recommended point-of-care, decentralised and laboratory independent molecular test Truenat by 90 per cent (made by Molbio Diagnostics), and WHO recommended molecular test (which requires semi-centralised infrastructure) Gene Xpert by 67 per cent (made by Cepheid). Microscopy increased during the same period by 68.1 per cent. But when we look at absolute numbers, the rise in microscopy dwarfs the historic scale up of molecular testing in India in 2022. Nearly 5.5 million more microscopy was done to find TB in 2022 compared to 2021whereas molecular testing for finding TB grew by almost 2 million in 2022 in India. Truenat is the largest used molecular test in India. The historic increase in molecular testing in India is a major public health achievement but, on the other hand, a steep increase in microscopy sparks serious concerns.
Neither science nor public health rationale will perhaps justify the increasing use of microscopy as a diagnostic test for TB when WHO recommended molecular tests exist. What does not exist is a proven track record globally to translate scientific breakthroughs into public health gains in a timely manner. If we can ensure that WHO recommended molecular tests are globally used upfront for every person with presumptive TB then when new TB tools come out of the research and development pipeline (such as TB vaccine) in the foreseeable future, we would have learned the pathway to reach the unreached. But as of now, this is not the case. Rollout of the new health technologies (including COVID-19 vaccines) is marred with inequity. Making molecular TB testing available to all with presumptive TB will accelerate efforts to find all TB and link all of them to proper TB care cascade (and thus end TB). It is also an opportunity for the world leaders to walk the talk on equitable rollout of health technologies.
Record-3: More quantum of solace: Thankfully, 2023 also saw Indian parliamentarians resonating the same level of commitment as the clarion call for a TB Free India given by the Indian Prime Minister. A Parliamentary Standing Committee Report which was presented to the Rajya Sabha and laid on the table of Lok Sabha on 21st September 2023, called upon the government to procure the #MadeInIndia and the WHO recommended (one of its kind globally) point-of-care, decentralised and laboratory independent molecular test Truenat “in bulk and supply the same at the minimum block levels across the country as quickly as possible, later on, which may be extended to primary health centres also. This would aid in the earliest realisation of upfront molecular testing across the country, which curbs the missing TB cases and simplifies the detection of drug- resistant TB cases.”
This report further recommended more investment in innovative TB diagnostic technologies. “Increased procurement of mobile diagnostic units with NAAT and hand-held x-rays for reaching out to remote or rural areas and other vulnerable areas” is in line with strong scientific evidence and already proven impact in active TB case finding worldwide.
Find all TB to stop TB: The WHO’s highest level initiative that calls upon governments for replacing microscopy 100% with upfront molecular testing for TB by 2027, was also endorsed by world leaders who committed to end TB at this year’s UN High Level meeting. This call to replace microscopy 100 per cent with upfront molecular testing is also echoed by over 400 endorsers of the Global Call to ‘Find All TB to Stop TB’ that was launched in Goa, India on 3rd November 2023. The Africa launch of this call took place at the largest AIDS conference in Africa on 8th December 2023 (22nd International Conference on AIDS and STIs in Africa).
This global call demands a paradigm shift from a lab-centric to a fundamentally people-centric model to find TB, leaving no one behind. It also reinforces the science-based call to reach the unreached by using WHO recommended point of care tools to screen and diagnose TB. If we act upon this key task, imagine the difference it will make when no TB case is missed, and all people with TB are brought into the care fold in a rights-based manner. A people-centric approach to find all TB, treat all TB, and prevent TB is critical to end TB.
When the going gets tough, the tough get going: India has made historic progress in scaling up WHO recommended molecular testing all across the country. With strongest political commitment at the highest level and recommendations enshrined in the recent parliamentary committee report, it is likely that 2024 could be a phenomenal year for finding all TB, treating all TB, and preventing all TB in India – a country which does not only have the highest TB burden but also a resolute will to build the strongest TB response to turn the tide and #endTB by 2025.
(Shobha Shukla and Bobby Ramakant lead the editorial team of CNS (Citizen News Service) and are on the Board of Global AMR Media Alliance (GAMA) and Asia Pacific Media Alliance for Health and Development (APCAT Media). Follow them on Twitter: @shobha1shukla, @bobbyramakant)
